Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
January 15, 2025 Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million Confirms Adjusted…
CertaraJanuary 15, 2025
Phoenix in the Future: Unveiling the Product Roadmap and the New TFL Module [APAC Webinar]
Principal Research Scientist Dr. Kristin Follman is a Principal Research Scientist at Certara, where she…
CertaraJanuary 15, 2025
Achieve Clinical Data Transparency with the 4 Cs of Collaboration
In this blog, we look at how you can enhance clinical data transparency and make…
CertaraJanuary 15, 2025
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region
The integration of MID3 offers a transformative opportunity for the MENA region to advance pharmaceutical…
CertaraJanuary 14, 2025
What 2025 could bring for psychedelic use in healthcare
Explore the evolving landscape of psychedelic medicine, featuring updates from key players and insights on…
CertaraJanuary 13, 2025
Unlock Global Regulatory Success: Overcoming Early Drug Development Challenges [APAC Webinar]
Navigating early drug development is critical to ensuring the long-term success of therapeutic candidates. This…
CertaraJanuary 10, 2025
Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters
January 10, 2025 Friedreich’s Ataxia (FA) is a rare, genetic, and progressive neurodegenerative disorder. A…
CertaraJanuary 10, 2025
